284 related articles for article (PubMed ID: 35074907)
41. RINT1 Regulates SUMOylation and the DNA Damage Response to Preserve Cellular Homeostasis in Pancreatic Cancer.
Arnold F; Gout J; Wiese H; Weissinger SE; Roger E; Perkhofer L; Walter K; Scheible J; Prelli Bozzo C; Lechel A; Ettrich TJ; Azoitei N; Hao L; Fürstberger A; Kaminska EK; Sparrer KMJ; Rasche V; Wiese S; Kestler HA; Möller P; Seufferlein T; Frappart PO; Kleger A
Cancer Res; 2021 Apr; 81(7):1758-1774. PubMed ID: 33531371
[TBL] [Abstract][Full Text] [Related]
42. Anti-pancreatic tumor efficacy of a Listeria-based, Annexin A2-targeting immunotherapy in combination with anti-PD-1 antibodies.
Kim VM; Blair AB; Lauer P; Foley K; Che X; Soares K; Xia T; Muth ST; Kleponis J; Armstrong TD; Wolfgang CL; Jaffee EM; Brockstedt D; Zheng L
J Immunother Cancer; 2019 May; 7(1):132. PubMed ID: 31113479
[TBL] [Abstract][Full Text] [Related]
43. Pancreatic Premalignant Lesions Secrete Tissue Inhibitor of Metalloproteinases-1, Which Activates Hepatic Stellate Cells Via CD63 Signaling to Create a Premetastatic Niche in the Liver.
Grünwald B; Harant V; Schaten S; Frühschütz M; Spallek R; Höchst B; Stutzer K; Berchtold S; Erkan M; Prokopchuk O; Martignoni M; Esposito I; Heikenwalder M; Gupta A; Siveke J; Saftig P; Knolle P; Wohlleber D; Krüger A
Gastroenterology; 2016 Nov; 151(5):1011-1024.e7. PubMed ID: 27506299
[TBL] [Abstract][Full Text] [Related]
44. Perineural Invasion Reprograms the Immune Microenvironment through Cholinergic Signaling in Pancreatic Ductal Adenocarcinoma.
Yang MW; Tao LY; Jiang YS; Yang JY; Huo YM; Liu DJ; Li J; Fu XL; He R; Lin C; Liu W; Zhang JF; Hua R; Li Q; Jiang SH; Hu LP; Tian GA; Zhang XX; Niu N; Lu P; Shi J; Xiao GG; Wang LW; Xue J; Zhang ZG; Sun YW
Cancer Res; 2020 May; 80(10):1991-2003. PubMed ID: 32098780
[TBL] [Abstract][Full Text] [Related]
45. Silencing ubiquitin-conjugating enzyme 2C inhibits proliferation and epithelial-mesenchymal transition in pancreatic ductal adenocarcinoma.
Wang X; Yin L; Yang L; Zheng Y; Liu S; Yang J; Cui H; Wang H
FEBS J; 2019 Dec; 286(24):4889-4909. PubMed ID: 31715067
[TBL] [Abstract][Full Text] [Related]
46. Pancreatic stellate cells and pancreas cancer: current perspectives and future strategies.
Haqq J; Howells LM; Garcea G; Metcalfe MS; Steward WP; Dennison AR
Eur J Cancer; 2014 Oct; 50(15):2570-82. PubMed ID: 25091797
[TBL] [Abstract][Full Text] [Related]
47. CD200 promotes immunosuppression in the pancreatic tumor microenvironment.
Choueiry F; Torok M; Shakya R; Agrawal K; Deems A; Benner B; Hinton A; Shaffer J; Blaser BW; Noonan AM; Williams TM; Dillhoff M; Conwell DL; Hart PA; Cruz-Monserrate Z; Bai XF; Carson WE; Mace TA
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32581043
[TBL] [Abstract][Full Text] [Related]
48. CDK1/2/5 inhibition overcomes IFNG-mediated adaptive immune resistance in pancreatic cancer.
Huang J; Chen P; Liu K; Liu J; Zhou B; Wu R; Peng Q; Liu ZX; Li C; Kroemer G; Lotze M; Zeh H; Kang R; Tang D
Gut; 2021 May; 70(5):890-899. PubMed ID: 32816920
[TBL] [Abstract][Full Text] [Related]
49. Spatially Resolved Multi-Omics Single-Cell Analyses Inform Mechanisms of Immune Dysfunction in Pancreatic Cancer.
Yousuf S; Qiu M; Voith von Voithenberg L; Hulkkonen J; Macinkovic I; Schulz AR; Hartmann D; Mueller F; Mijatovic M; Ibberson D; AlHalabi KT; Hetzer J; Anders S; Brüne B; Mei HE; Imbusch CD; Brors B; Heikenwälder M; Gaida MM; Büchler MW; Weigert A; Hackert T; Roth S
Gastroenterology; 2023 Oct; 165(4):891-908.e14. PubMed ID: 37263303
[TBL] [Abstract][Full Text] [Related]
50. Monitoring and functional characterization of the lymphocytic compartment in pancreatic ductal adenocarcinoma patients.
Oberg HH; Grage-Griebenow E; Adam-Klages S; Jerg E; Peipp M; Kellner C; Petrick D; Gonnermann D; Freitag-Wolf S; Röcken C; Sebens T; Vogel I; Becker T; Ebsen M; Kabelitz D; Wesch D; Sebens S
Pancreatology; 2016; 16(6):1069-1079. PubMed ID: 27424476
[TBL] [Abstract][Full Text] [Related]
51. Pancreatic cancer: Emerging field of regulatory B-cell-targeted immunotherapies.
Senturk ZN; Akdag I; Deniz B; Sayi-Yazgan A
Front Immunol; 2023; 14():1152551. PubMed ID: 37033931
[TBL] [Abstract][Full Text] [Related]
52. miR-128 Regulates Tumor Cell CD47 Expression and Promotes Anti-tumor Immunity in Pancreatic Cancer.
Xi Q; Chen Y; Yang GZ; Zhang JY; Zhang LJ; Guo XD; Zhao JY; Xue ZY; Li Y; Zhang R
Front Immunol; 2020; 11():890. PubMed ID: 32536914
[TBL] [Abstract][Full Text] [Related]
53. The reciprocal regulation between host tissue and immune cells in pancreatic ductal adenocarcinoma: new insights and therapeutic implications.
Liu X; Xu J; Zhang B; Liu J; Liang C; Meng Q; Hua J; Yu X; Shi S
Mol Cancer; 2019 Dec; 18(1):184. PubMed ID: 31831007
[TBL] [Abstract][Full Text] [Related]
54. circCUL2 induces an inflammatory CAF phenotype in pancreatic ductal adenocarcinoma via the activation of the MyD88-dependent NF-κB signaling pathway.
Zheng S; Hu C; Lin H; Li G; Xia R; Zhang X; Su D; Li Z; Zhou Q; Chen R
J Exp Clin Cancer Res; 2022 Feb; 41(1):71. PubMed ID: 35189958
[TBL] [Abstract][Full Text] [Related]
55. Combination cancer immunotherapy targeting TNFR2 and PD-1/PD-L1 signaling reduces immunosuppressive effects in the microenvironment of pancreatic tumors.
Zhang X; Lao M; Xu J; Duan Y; Yang H; Li M; Ying H; He L; Sun K; Guo C; Chen W; Jiang H; Zhang X; Bai X; Liang T
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35260434
[TBL] [Abstract][Full Text] [Related]
56. Dynamic profiling of immune microenvironment during pancreatic cancer development suggests early intervention and combination strategy of immunotherapy.
Yang J; Zhang Q; Wang J; Lou Y; Hong Z; Wei S; Sun K; Wang J; Chen Y; Sheng J; Su W; Bai X; Liang T
EBioMedicine; 2022 Apr; 78():103958. PubMed ID: 35316682
[TBL] [Abstract][Full Text] [Related]
57. Targeting LIF-mediated paracrine interaction for pancreatic cancer therapy and monitoring.
Shi Y; Gao W; Lytle NK; Huang P; Yuan X; Dann AM; Ridinger-Saison M; DelGiorno KE; Antal CE; Liang G; Atkins AR; Erikson G; Sun H; Meisenhelder J; Terenziani E; Woo G; Fang L; Santisakultarm TP; Manor U; Xu R; Becerra CR; Borazanci E; Von Hoff DD; Grandgenett PM; Hollingsworth MA; Leblanc M; Umetsu SE; Collisson EA; Scadeng M; Lowy AM; Donahue TR; Reya T; Downes M; Evans RM; Wahl GM; Pawson T; Tian R; Hunter T
Nature; 2019 May; 569(7754):131-135. PubMed ID: 30996350
[TBL] [Abstract][Full Text] [Related]
58. CXCR1/2 dual-inhibitor ladarixin reduces tumour burden and promotes immunotherapy response in pancreatic cancer.
Piro G; Carbone C; Agostini A; Esposito A; De Pizzol M; Novelli R; Allegretti M; Aramini A; Caggiano A; Granitto A; De Sanctis F; Ugel S; Corbo V; Martini M; Lawlor RT; Scarpa A; Tortora G
Br J Cancer; 2023 Jan; 128(2):331-341. PubMed ID: 36385556
[TBL] [Abstract][Full Text] [Related]
59. Targeting SUMO Signaling to Wrestle Cancer.
Kroonen JS; Vertegaal ACO
Trends Cancer; 2021 Jun; 7(6):496-510. PubMed ID: 33353838
[TBL] [Abstract][Full Text] [Related]
60. Prosaposin, tumor-secreted protein, promotes pancreatic cancer progression by decreasing tumor-infiltrating lymphocytes.
Miyahara Y; Takano S; Sogawa K; Tomizawa S; Furukawa K; Takayashiki T; Kuboki S; Ohtsuka M
Cancer Sci; 2022 Aug; 113(8):2548-2559. PubMed ID: 35633503
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]